Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy

Introduction: Patients with hematologic malignancies are at an increased risk of morbidity and mortality from COVID-19 disease (Vijenthira, Blood 2020). This is likely a result of combination of immunodeficiency conferred by the disease and the therapeutics. The immunogenicity of the COVID-19 vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahiya, Saurabh, Luetkens, Tim, Avila, Stephanie, Margiotta, Philip, Hankey, Kim, Lesho, Patricia, Bauman, Sherri, Smith, Nancy, Ruehle, Kathleen, Lee, Seung-Tae, Law, Jennie Y., Baddley, John, Kocoglu, Mehmet Hakan, Yared, Jean A., Hardy, Nancy M., Rapoport, Aaron P., Atanackovic, Djordje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
704.Cellular Immunotherapies: Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701648/
http://dx.doi.org/10.1182/blood-2021-153949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701648/
http://dx.doi.org/10.1182/blood-2021-153949

Ejemplares similares